Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 31

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 31
---
ages of research and development with the vaccine and ARB new product candidates. These new indications and product candidates will
require significant costs to advance through the development stages. Even if such product candidates are advanced through clinical trials,
the results of such trials may not gain FDA approval. Even if approved, our products may not be commercially successful.

<div align='center'>15</div>

Risks Related to Protection of our Intellectual Property

Our pending patent applications may not result in issued patents, and any patents that may be granted could include only limited claims. As a result, our intellectual property protection may be weaker than anticipated, which could make it more difficult for us to establish or maintain a competitive position.

The patent application process is subject to
numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our drug candidates by obtaining
and defending patents. We have pending and issued U.S. and foreign patents and patent applications covering our drug candidates; however,
we cannot predict:

| ● | if                                                           
 and when patents nay issue based on our patent applications; |

| ● | the                                                                         
 scope of protection of any patent issuing based on our patent applications; |

| ● | whether                                                                      
 the claims of any issued patent will provide protection against competitors; |

| ● | whether                                                                                    
 we will need to initiate litigation or administrative proceedings to enforce and/or defend 
 our patent rights which will be costly whether we win or lose; and/or                      |

| ● | whether                                                                                  
 the patent applications will result in issued patents with claims that cover each of our 
 drug candidates or uses thereof in the United States or in other foreign countries.      |

We may be subject to a third-party pre-issuance
submission of prior art to the USPTO or become involved in post-grant review procedures, oppositions, derivations, revocation, reexaminations,
inter partes review or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights
of others. An adverse determination in any such challenge may result in loss of exclusivity or in our patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical
technology and products or limit the duration of the patent protection of our technology and products. Such challenges also may result
in substantial costs and require significant time from our scientists and management, even if the eventual outcome is favorable to us.
Any of